MA53827A - Modulateurs de l'alpha -1 antitrypsine - Google Patents
Modulateurs de l'alpha -1 antitrypsineInfo
- Publication number
- MA53827A MA53827A MA053827A MA53827A MA53827A MA 53827 A MA53827 A MA 53827A MA 053827 A MA053827 A MA 053827A MA 53827 A MA53827 A MA 53827A MA 53827 A MA53827 A MA 53827A
- Authority
- MA
- Morocco
- Prior art keywords
- alpha
- antitrypsin
- modulators
- antitrypsin modulators
- Prior art date
Links
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862742148P | 2018-10-05 | 2018-10-05 | |
US201862768662P | 2018-11-16 | 2018-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53827A true MA53827A (fr) | 2021-09-15 |
Family
ID=69467663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053827A MA53827A (fr) | 2018-10-05 | 2019-10-04 | Modulateurs de l'alpha -1 antitrypsine |
Country Status (16)
Country | Link |
---|---|
US (2) | US11623924B2 (fr) |
EP (1) | EP3860712A1 (fr) |
JP (1) | JP2022512588A (fr) |
KR (1) | KR20210089656A (fr) |
CN (1) | CN113164761A (fr) |
AU (1) | AU2019362753A1 (fr) |
BR (1) | BR112021006392A2 (fr) |
CA (1) | CA3114672A1 (fr) |
CO (1) | CO2021005884A2 (fr) |
IL (1) | IL281884A (fr) |
JO (1) | JOP20210060A1 (fr) |
MA (1) | MA53827A (fr) |
MX (1) | MX2021003819A (fr) |
TW (1) | TW202024091A (fr) |
UY (1) | UY38403A (fr) |
WO (1) | WO2020081257A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113164761A (zh) | 2018-10-05 | 2021-07-23 | 弗特克斯药品有限公司 | α-1抗胰蛋白酶的调节剂 |
UY38696A (es) * | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
TW202116303A (zh) * | 2019-10-02 | 2021-05-01 | 美商維泰克斯製藥公司 | α—1抗胰蛋白酶缺乏症之治療方法 |
GB201918410D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
GB201918404D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of aplha1-antitrypsin deficiency |
GB201918414D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency |
GB201918416D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency |
GB201918413D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
CA3179184A1 (fr) * | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Modulateurs d'alpha 1 antitrypsine |
GB202009074D0 (en) | 2020-06-15 | 2020-07-29 | Z Factor Ltd | Compound |
BR112023001537A2 (pt) | 2020-07-27 | 2023-04-11 | Vertex Pharma | Processos para preparar moduladores de alfa-1 antitripsina |
WO2022104353A1 (fr) | 2020-11-12 | 2022-05-19 | Vertex Pharmaceuticals Incorporated | Procédés de surveillance du déficit en aat |
KR20230110313A (ko) * | 2020-11-17 | 2023-07-21 | 버텍스 파마슈티칼스 인코포레이티드 | 4-(5-(4-플루오로페닐)-6-(테트라하이드로-2H-피란-4-일)-1,5-디하이드로피롤로[2,3-f]인다졸-7-일)벤조산의 고형분 형태 |
GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
CN114605385B (zh) * | 2022-03-25 | 2023-09-08 | 河南大学 | 吲哚哌啶脲类trpv1拮抗/faah抑制双靶点药物及制备方法和应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE790679A (fr) * | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
DK158590D0 (da) | 1990-07-02 | 1990-07-02 | Lundbeck & Co As H | Indolderivater |
JP2000072751A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体 |
JP2000281654A (ja) | 1999-03-26 | 2000-10-10 | Tanabe Seiyaku Co Ltd | イソキノリン誘導体 |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
FR2802532A1 (fr) | 1999-12-17 | 2001-06-22 | Sanofi Synthelabo | Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique |
US6638929B2 (en) | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
KR20030019621A (ko) | 2000-07-26 | 2003-03-06 | 스미스클라인비이참피이엘시이 | 항균 활성을 갖는 아미노피페리딘 퀴놀린 및 그의아자이소스테릭 유사체 |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
CN1612866A (zh) | 2001-11-14 | 2005-05-04 | 特瓦制药工业有限公司 | 无定形和结晶形的氯沙坦钾及其制备方法 |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2011056222A1 (fr) | 2009-11-05 | 2011-05-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Procédés de traitement de troubles associés à une agrégation protéique |
US20110224229A1 (en) | 2010-03-10 | 2011-09-15 | Astrazeneca Ab | Novel Crystalline Form |
US9572794B2 (en) | 2014-08-06 | 2017-02-21 | Vanderbilt University | Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists |
WO2016154051A1 (fr) | 2015-03-20 | 2016-09-29 | University Of Florida Research Foundation, Inc. | Polythérapie pour le traitement de maladies infectieuses |
US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
EP3699179A4 (fr) | 2017-10-19 | 2021-06-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Dérivé tricyclique contenant du pyrazolyle, son procédé de préparation et son utilisation |
AU2018360577A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid X receptor modulators |
CN107698505A (zh) | 2017-11-20 | 2018-02-16 | 孙婷婷 | 一种诺得司他的制备方法 |
RS63623B1 (sr) | 2017-12-13 | 2022-10-31 | Lupin Ltd | Supstituisana biciklična heterociklična jedinjenja kao inhibitori prmt5 |
WO2019149522A1 (fr) | 2018-01-31 | 2019-08-08 | Merck Patent Gmbh | Composés de quinoléine en tant qu'inhibiteurs d'irak et leurs utilisations |
CA3103920A1 (fr) | 2018-06-22 | 2019-12-26 | Ucl Business Ltd | Composes pour traiter les maladies mediees par l'alpha 1 antitrypsine |
CA3108388A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
CN113164761A (zh) | 2018-10-05 | 2021-07-23 | 弗特克斯药品有限公司 | α-1抗胰蛋白酶的调节剂 |
CN110776459B (zh) | 2019-03-19 | 2023-01-24 | 江苏知原药业股份有限公司 | 7-羟基-2-喹诺酮-二硫代氨基甲酸酯类胆碱酯酶抑制剂 |
UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
TW202116303A (zh) | 2019-10-02 | 2021-05-01 | 美商維泰克斯製藥公司 | α—1抗胰蛋白酶缺乏症之治療方法 |
KR20220133227A (ko) | 2020-01-30 | 2022-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 알파-1 항트립신 결핍증의 치료 방법 |
CA3177524A1 (fr) | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Modulateurs d'alpha 1 antitrypsine |
WO2021203014A1 (fr) | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrano [4,3-b] indole en tant que modulateurs d'alpha-1-antitrypsine pour traiter une déficience en alpha-1-antitrypsine (aatd) |
EP4126863A1 (fr) | 2020-04-03 | 2023-02-08 | Vertex Pharmaceuticals Incorporated | Dérivés de 1h-pyrazolo [4,3-g] isoquinoléine et de 1h-pyrazolo [4,3-g] quinoléine en tant que modulateurs d'alpha-1-antitrypsine pour traiter une déficience en alpha-1-antitrypsine (aatd) |
CN115916748A (zh) | 2020-04-03 | 2023-04-04 | 弗特克斯药品有限公司 | 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的吲哚衍生物 |
CA3179184A1 (fr) | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Modulateurs d'alpha 1 antitrypsine |
CA3179189A1 (fr) | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | Modulateurs d'alpha 1 antitrypsine |
BR112023001537A2 (pt) | 2020-07-27 | 2023-04-11 | Vertex Pharma | Processos para preparar moduladores de alfa-1 antitripsina |
-
2019
- 2019-10-04 CN CN201980078980.8A patent/CN113164761A/zh active Pending
- 2019-10-04 US US16/593,118 patent/US11623924B2/en active Active
- 2019-10-04 JO JOP/2021/0060A patent/JOP20210060A1/ar unknown
- 2019-10-04 JP JP2021518181A patent/JP2022512588A/ja active Pending
- 2019-10-04 MA MA053827A patent/MA53827A/fr unknown
- 2019-10-04 AU AU2019362753A patent/AU2019362753A1/en active Pending
- 2019-10-04 EP EP19848828.0A patent/EP3860712A1/fr active Pending
- 2019-10-04 WO PCT/US2019/054681 patent/WO2020081257A1/fr active Application Filing
- 2019-10-04 MX MX2021003819A patent/MX2021003819A/es unknown
- 2019-10-04 CA CA3114672A patent/CA3114672A1/fr active Pending
- 2019-10-04 KR KR1020217013514A patent/KR20210089656A/ko active Search and Examination
- 2019-10-04 BR BR112021006392A patent/BR112021006392A2/pt unknown
- 2019-10-05 TW TW108136173A patent/TW202024091A/zh unknown
- 2019-10-07 UY UY0001038403A patent/UY38403A/es unknown
-
2021
- 2021-03-29 IL IL281884A patent/IL281884A/en unknown
- 2021-05-05 CO CONC2021/0005884A patent/CO2021005884A2/es unknown
-
2023
- 2023-02-09 US US18/107,786 patent/US20230265080A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113164761A (zh) | 2021-07-23 |
CA3114672A1 (fr) | 2020-04-23 |
JOP20210060A1 (ar) | 2023-01-30 |
TW202024091A (zh) | 2020-07-01 |
EP3860712A1 (fr) | 2021-08-11 |
US11623924B2 (en) | 2023-04-11 |
UY38403A (es) | 2020-04-30 |
MX2021003819A (es) | 2021-06-23 |
US20210179587A1 (en) | 2021-06-17 |
CO2021005884A2 (es) | 2021-05-20 |
BR112021006392A2 (pt) | 2021-07-06 |
AU2019362753A1 (en) | 2021-05-20 |
IL281884A (en) | 2021-05-31 |
US20230265080A1 (en) | 2023-08-24 |
KR20210089656A (ko) | 2021-07-16 |
WO2020081257A1 (fr) | 2020-04-23 |
JP2022512588A (ja) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53827A (fr) | Modulateurs de l'alpha -1 antitrypsine | |
CL2021001078A1 (es) | 2-amino-n-heteroarilo-nicotinamidas como inhibidores de nav1.8. | |
DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
MA54386A (fr) | Modulateurs de trex1 | |
IT201800003333A1 (it) | Veicolo modulare | |
MA46615A (fr) | Inhibiteurs de nav1.7 de type acyl-sulfonamide | |
DK3801427T3 (da) | Selvbalancerende køretøj | |
MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
ES1216564Y (es) | Dispensador de fundas de protección manual | |
DK3840596T3 (da) | Sammensætning | |
MA51645A (fr) | Modulateurs de l'expression de dnm2 | |
DK3840144T3 (da) | Skifteanordningen | |
MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
ES1225190Y (es) | Conjunto de ducha | |
DK3969126T3 (da) | Deodorantsammensætning | |
ITUA20163609A1 (it) | "micro-cogeneratore". | |
ES1230426Y (es) | Aparcavehiculos modular escamoteable | |
ES1232554Y (es) | Bolardo de senalizacion viaria | |
ES1242619Y (es) | Arenero | |
UA37466S (uk) | Крапельниця | |
UA42087S (uk) | Несесер дорожній | |
UA42085S (uk) | Несесер дорожній | |
UA42083S (uk) | Несесер дорожній |